References
Denning DW et al. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 12: 1147-1201, 1990.
Denning DW et al. NIAID Mycoses Study Group multicenter of oral itraconazole therapy for invasive aspergillosis. American Journal of Medicine 97: 135-144, 1994.
Holding KJ et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clinical Infectious Diseases 31(5): 1253-1257, 2000.
Keating J et al. Management of pulmonary aspergillosis in AIDS: an emerging clinical problem. Journal of Clinical Pathology 47(9): 805-809, 1994.
Klapholz A et al. Aspergillosis in the acquired immunodeficiency syndrome. Chest 100: 1614-1618, 1991.
Maertens J et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, AMB lipid formulations or azoles. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, abstract 1103, 2000.
Minamoto et al. Invasive aspergillosis in patients with AIDS. Clinical Infectious Diseases 14: 66-74, 1992.
Moreno A et al. Role of antiretroviral therapy in long-term survival of patients with AIDS-related pulmonary aspergillosis. European Journal of Clinical Microbiology and Infectious Diseases 19(9): 688-689, 2000.
Pursell et al. Aspergillus species colonization and invasive disease in patients with AIDS. Clinical Infectious Diseases 14: 141-148, 1992.
latest aidsmap news
- High rate of death amongst patients with HIV diagnosed late
- CD4 cell count increases sustained up to five years in developing-world treatment programmes
- Raltegravir may have role in PEP if exposure involves drug-resistant HIV
- Excellent outcomes from five years of antiretroviral use in Botswana
- Study explores verbal and non-verbal communication in unprotected sex between men
- IL-2 provides quick ‘AIDS rescue’, but effect does not always last
- Once-a-day etravirine should work as first-line treatment
- Second-line combinations fail twice as often as first-line ones in the first year
- If you can't switch, better to stay on failing treatment than stop it, studies show
- Non-nucleoside resistance is efficiently transmitted within infection ‘clusters’
